Published • loading... • Updated
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
The complaint says AEVEX hid a prearranged lock-up waiver and secondary offering that generated $207.9 million for its private equity owner.
- On Monday, Bronstein, Gewirtz & Grossman, LLC announced a class action lawsuit against AEVEX Corp. on behalf of investors who purchased AEVEX Class A common stock between April 17, 2026, and June 4, 2026.
- According to the complaint, defendants allegedly pre-arranged a plan to waive the 180-day lock-up restriction and conduct a secondary public offering shortly after the IPO.
- Investors allege the secondary public offering generated $207.9 million for AEVEX's controlling private equity owner, while the company itself received no proceeds from the SPO.
- Eligible AEVEX investors have until October 20, 2026, to request lead plaintiff status from the Court; Bronstein, Gewirtz & Grossman, LLC represents them on contingency.
- Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC, said, "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.
Insights by Ground AI
3 Articles
3 Articles
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
